Nikhil Prasad Fact checked by:Thailand Medical News Team Jul 25, 2024 5 months, 5 hours, 31 minutes ago
Medical News: Researchers from Poland Unveil Important Findings on Ear Involvements in Vasculitis
In a recent study conducted by researchers at the Military Institute of Medicine in Warsaw, Poland, significant insights into the aural manifestations of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) were uncovered. This
Medical News report explores the findings and implications of their study, focusing on how this condition affects hearing and the best approaches for diagnosis and treatment.
A new look at ANCA-associated vasculitis and its impact on hearing
Understanding ANCA-Associated Vasculitis
ANCA-associated vasculitis (AAV) is a group of diseases that affect small and medium-sized blood vessels, leading to inflammation and damage in various organs. The primary types of AAV are Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). These conditions are complex and can impact almost any part of the body, including the ears.
Aural Manifestations of AAV
One of the lesser-known but significant impacts of AAV is its effect on hearing. The study findings highlight that ear involvement is common in AAV, particularly in GPA. Symptoms can range from mild to severe and include hearing loss, otitis media with effusion, and even facial palsy.
Key Findings
-Hearing Loss and Otitis Media
Hearing loss is a prevalent symptom among AAV patients. The study found that about 30-60% of GPA patients experience some form of ear involvement, while MPA and EGPA cases are slightly lower. One of the critical conditions identified is Otitis Media with ANCA-Associated Vasculitis (OMAAV), characterized by persistent otitis media resistant to standard treatments.
-Facial Palsy
Another significant finding is the occurrence of facial palsy in AAV patients, which can be particularly distressing. The study reports that facial palsy is more frequent in women and often correlates with hypertrophic pachymeningitis, a severe inflammation of the dura mater.
Diagnosis Challenges and Criteria
Diagnosing OMAAV can be challenging due to its rarity and the overlap of symptoms with other conditions. The researchers outlined specific diagnostic criteria for OMAAV, which include persistent otitis media, hearing deterioration, and positive ANCA serology. A notable diagnostic tool mentioned is the SCOT (Scoring System of OMAAV Tympanic Membrane), which helps differentiate OMAAV from other types of otitis media based on the evaluation of the tympanic membrane and external acoustic meatus.
Treatment Approaches
Pharmacological Treatment The primary treatment for AAV, including OMAAV, involves immunosuppressive therapy. The standard induction therapy includes drugs like rituximab (RTX) or cyclophosphamide (CYC) combined with glucocorticoids (GC). For no
n-life-threatening forms, methotrexate or mycophenolate mofetil may be used. Maintenance therapy, which follows the induction phase, often involves low-dose glucocorticoids combined with drugs like azathioprine or methotrexate.
Surgical Interventions Surgery is generally not the first line of treatment due to the risk of exacerbating the condition. However, in cases where hearing loss is severe and persistent despite medical therapy, surgical options like cochlear implants may be considered. The study highlights the importance of performing such surgeries during remission phases to avoid complications.
Prognosis and Follow-Up
The prognosis for AAV patients with ear involvement can vary. The study emphasizes the importance of early diagnosis and aggressive treatment to prevent irreversible damage. Regular follow-ups and hearing assessments are crucial for managing the condition effectively.
Conclusion
The study by Dr Michał S. Kaczmarczyk, Dr Dariusz Jurkiewicz, Dr Stanisław Niemczyk, and Dr Aleksandra Rymarz from the Military Institute of Medicine provides critical insights into the diagnosis and treatment of ear involvement in ANCA-associated vasculitis. Their findings underscore the need for heightened awareness and collaboration among medical professionals to improve outcomes for patients suffering from this complex condition.
The study findings were published in the peer-reviewed Journal of Clinical Medicine.
https://www.mdpi.com/2077-0383/13/15/4298
For the latest on Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/autopsy-study-shows-acute-neutrophilic-vasculitis-leukocytoclasia-in-brains-of-those-who-died-from-covid-19
https://www.thailandmedical.news/news/breaking-physicians-at-university-of-california-san-diego-report-about-young-healthy-covid-19-patient-developing-cns-lymphocytic-vasculitis
Share
Tweet
Share
